Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | IDH1 | O75874 | 2/20 | 0.36 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 5/20 | 0.34 |
| ▸ | CDK9 | P50750 | 5/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.34 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | VNN1 | O95497 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.33 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.33 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10275650 | 0.84 | FLT3 (0.38) | — | |
| SCHEMBL10276542 | 0.84 | BRD4 (0.41) | BRD4IDH1EGLN2CCNT1CDK9 | |
| SCHEMBL10275571 | 0.80 | MAPK14 (0.35) | KCNH2 | |
| SCHEMBL10282687 | 0.79 | BRD4 (0.43) | BRD4IDH1EGLN2CCNT1CDK9 | |
| SCHEMBL10275495 | 0.72 | TNKS2 (0.36) | KCNH2 | |
| SCHEMBL10276351 | 0.70 | TRPV1 (0.37) | HDAC6 | |
| SCHEMBL10276020 | 0.70 | ALDH1A1 (0.44) | — | |
| SCHEMBL10275828 | 0.69 | KMT2A (0.42) | — | |
| SCHEMBL10313875 | 0.68 | BRD4 (0.39) | BRD4IDH1EGLN2CCNT1CDK9 | |
| SCHEMBL10313547 | 0.68 | DHODH (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | claimed |
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | TYMP, TYMS, ADORA3 | BRD4 3228/4885IDH1 696/4885EGLN2 4250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.